apanese firm Yakult Honsha Co. Ltd. completed phase I trials for resminostat – licensed from German firm 4SC AG – in solid tumors, as the partners hope to move forward with the target indication of hepatocellular carcinoma (HCC) in Japan, where liver cancer is one of the largest causes of cancer-related death.